WRF
HZNP

Waddell & Reed Financial’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Waddell & Reed Financial’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$120M Buy
+1,305,422
New +$110M 0.25% 124
2015
Q4 		– Sell
-245,000
Closed -$4.86M – 663
2015
Q3 		$4.86M Buy
+245,000
New +$7.74M 0.01% 499

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Waddell & Reed Financial's HZNP Position: Q1 2021 in Review

Waddell & Reed Financial opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2021: 1,305,422 shares worth $120M. The stake represents 0.25% of the portfolio and ranks #124 among its holdings. This is a return to the name: Waddell & Reed Financial previously reported a position in HZNP as recently as Q3 2015.

Waddell & Reed Financial first reported a position in HZNP in Q3 2015 and has held it in 2 quarters since. 516 funds tracked by Wall St. Rank hold HZNP as of Q1 2021.

  • Waddell & Reed Financial held 1,305,422 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $120M as of Q1 2021.
  • Horizon Therapeutics Public Limited Company Ordinary Shares was a new Waddell & Reed Financial position in Q1 2021.
  • Horizon Therapeutics Public Limited Company Ordinary Shares made up 0.25% of Waddell & Reed Financial's portfolio in Q1 2021, its #124 holding.
  • Waddell & Reed Financial first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2015 and has held it in 2 quarters since.
  • 516 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2021.

Based on Waddell & Reed Financial's 13F filing for Q1 2021, filed 12 May 2021.